A mouse model for testing remyelinating therapies
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Used in combination with immunomodulatory therapies, remyelinating therapies are a viable therapeutic approach for treating individuals with multiple sclerosis. Studies of postmortem MS brains identified greater remyelination in demyelinated cerebral cortex than in demyelinated brain white matter and implicated reactive astrocytes as an inhibitor of white matter remyelination. An animal model that recapitulates these phenotypes would benefit the development of remyelination therapeutics. We have used a modified cuprizone protocol that causes a consistent and robust demyelination of mouse white matter and cerebral cortex. Spontaneous remyelination occurred significantly faster in the cerebral cortex than in white matter and reactive astrocytes were more abundant in white matter lesions. Remyelination of white matter and cerebral cortex was therapeutically enhanced by daily injections of thyroid hormone triiodothronine (T3). In summary, we describe an in vivo demyelination/remyelination paradigm that can be powered to determine efficacy of therapies that enhance white matter and cortical remyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544 · cited 3×
“…of remyelination of large diameter axons (Michailov et al., 2004), the use of g-ratio as an indicator of remyelination of small diameter axons in the corpus callosum has been controversial (Franklin and Ffrench-Constant, 2008; Klopfleisch et al., 2008; Mason et al., 2001; Moore et Exp Neurol.”
BackgroundMethodMatsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984
Myelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation
Kotter, M. R., Li, W.-W., Zhao, C., & Franklin, R. J. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2615-05.2006 · Cited by 768
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621 · cited 1×
“Degeneration of demyelinated axons is a major cause of permanent neurological disability in individuals with MS. Remyelination restores saltatory conduction and provides trophic support that enhances axon survival (Crawford et al., 2009; Duncan et al., 2009; Trapp and Stys, 2009).”
BackgroundSelf-citationHyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 3×
“…activation of astrocytes and microglia, and increased levels of hyaluronan and hyaluronan-binding membrane protein following 12 weeks of cup/rap demyelination of white matter compared to gray matter, similar to what was described in postmortem MS brains (Back et al., 2005; Chang et al., 2012).”
BackgroundResultSelf-citationPathophysiology of the brain extracellular matrix: a new target for remyelination
Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S., & Yong, V. W. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3550 · Cited by 549 · cited 2×
“…proposed that the decreased rate of white matter remyelination in MS brains was influenced by reactive astrocytes which secrete and organize extracellular matrix proteins that inhibit oligodendrocyte differentiation and myelination (Lau et al., 2013; Ponta et al., 2003; Sherman and Back, 2008).”
BackgroundRetinoid X receptor gamma signaling accelerates CNS remyelination
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kerninon, C., Williams, A., Krezel, W., Kagechika, H., Bauer, J., Zhao, C., Evercooren, A. B.-V., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2702 · Cited by 547
TREM2 sustains microglial expansion during aging and response to demyelination
Poliani, P. L., Wang, Y., Fontana, E., Robinette, M. L., Yamanishi, Y., Gilfillan, S., & Colonna, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77983 · Cited by 525 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript al., 2014; Poliani et al., 2015; Stidworthy et al., 2003).”
Background
Cited by
Remyelination therapies: a new direction and challenge in multiple sclerosis
Plemel, J. R., Liu, W.-Q., & Yong, V. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.115 · Cited by 281
Ferroptosis Mediates Cuprizone-Induced Loss of Oligodendrocytes and Demyelination
Jhelum, P., Santos-Nogueira, E., Teo, W., Haumont, A., Lenoël, I., Stys, P. K., & David, S. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1749-20.2020 · Cited by 214
Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases
Vega-Riquer, J. M., Mendez-Victoriano, G., Morales-Luckie, R. A., & Gonzalez-Perez, O. (2019) · Current Neuropharmacology · doi:10.2174/1570159x15666170717120343 · Cited by 188
Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS
Jhelum, P., Zandee, S., Ryan, F., Zarruk, J. G., Michalke, B., Venkataramani, V., Curran, L., Klement, W., Prat, A., & David, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01617-7 · Cited by 49
Yamate-Morgan, H., Lauderdale, K., Horeczko, J., Merchant, U., & Tiwari-Woodruff, S. K. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.038 · Cited by 27
“Compelled by the prospect of achieving more complete demyelination within our model, in a recent evaluation of a therapeutic agent, we included rapamycin as advised by the current literature (Narayanan et al., 2009; Sachs et al., 2014; Bai et al., 2016).”
BackgroundMethodInfluential
Metadata
- Authors
- Bai, C. B., Sun, S., Roholt, A., Benson, E., Edberg, D., Medicetty, S., Dutta, R., Kidd, G., Macklin, W. B., & Trapp, B.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 283
- Issue
- Pt A
- Pages
- 330-340
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2470033627
- Cited by
- 65
- References
- 31
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A mouse model for testing remyelinating therapies. https://app.cochat.ai/papers/10.1016/j.expneurol.2016.06.033
- The paper
- Bai, C. B., Sun, S., Roholt, A., Benson, E., Edberg, D., Medicetty, S., Dutta, R., Kidd, G., Macklin, W. B., & Trapp, B. (2016). A mouse model for testing remyelinating therapies. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2016.06.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.